Shuttle Pharmaceuticals Announces Agreement Changes and Exit Costs
Ticker: SHPH · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001, $300,000, $557,000, $750,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement, termination, restructuring
TL;DR
Shuttle Pharma changed up some big deals and is taking exit costs. Big moves ahead.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. announced on November 20, 2025, the entry into a material definitive agreement and the termination of a material definitive agreement. The company also reported costs associated with exit or disposal activities. Specific details regarding the agreements and costs were not provided in this filing.
Why It Matters
This filing indicates significant shifts in the company's contractual landscape and potential restructuring, which could impact future operations and financial performance.
Risk Assessment
Risk Level: medium — The termination of agreements and associated exit costs suggest potential financial strain or strategic shifts that carry inherent business risks.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- November 20, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Gaithersburg, MD (location) — Principal executive offices
FAQ
What was the nature of the material definitive agreement entered into by Shuttle Pharmaceuticals?
The filing states that Shuttle Pharmaceuticals Holdings, Inc. entered into a material definitive agreement, but the specific details of this agreement are not disclosed in this current report.
What led to the termination of the material definitive agreement?
The filing reports the termination of a material definitive agreement, but the reasons or terms of this termination are not specified in the provided document.
What are the 'Cost Associated with Exit or Disposal Activities' mentioned in the filing?
The filing indicates that Shuttle Pharmaceuticals Holdings, Inc. has costs associated with exit or disposal activities, but the exact nature and amount of these costs are not detailed in this report.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 20, 2025.
Where are Shuttle Pharmaceuticals Holdings, Inc.'s principal executive offices located?
Shuttle Pharmaceuticals Holdings, Inc.'s principal executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
Filing Stats: 955 words · 4 min read · ~3 pages · Grade level 12.2 · Accepted 2025-11-21 16:05:45
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
- $300,000 — e Company will pay a partial payment of $300,000 to Theradex as full and final payment o
- $557,000 — ny to Theradex, totalling approximately $557,000 (the "Outstanding Liabilities") and in
- $750,000 — mates these amounts to be approximately $750,000. Item 1.02. Termination of a Material
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex10-1.htm (EX-10.1) — 38KB
- 0001493152-25-024618.txt ( ) — 252KB
- shph-20251120.xsd (EX-101.SCH) — 3KB
- shph-20251120_lab.xml (EX-101.LAB) — 33KB
- shph-20251120_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Date: November 21, 2025 By: /s/ Christopher Cooper Christopher Cooper Interim Chief Executive Officer